Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients ( ≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study

CONCLUSION: The study demonstrated that individuals older than 65 years with locally advanced or metastatic ESCC have a survival benefit from the first-line treatment of PD-1 inhibitors combined therapy, with a manageable safety profile.PMID:38602642 | DOI:10.1007/s12094-024-03453-0

Source: Cancer Control - April 11, 2024 Category: Cancer & Oncology Authors: Yi Yu Tao Wu Wei Gan Can Liu Ran Zhang Jinxiu Zheng Jianping Xiong Jun Chen Junhe Li Source Type: research